Form 4: Disc Medicine CMO Executes Planned Stock Sale

Chief Medical Officer William Jacob Savage sold 5,731 shares of Disc Medicine, Inc. common stock via a 10b5-1 trading plan.

Summary

• William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc., sold a total of 5,731 shares of common stock on April 13, 2026.
• The sales were executed in two tranches: 3,531 shares at a weighted average price of $66.1209 and 2,200 shares at a weighted average price of $66.8073.
• Following these transactions, the reporting person retains beneficial ownership of 79,480 shares of common stock.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 2, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established 10b5-1 plan, which is a standard administrative procedure for corporate officers.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell stock without concerns regarding insider trading.

Negatives

• The transaction represents a reduction in the equity stake held by a key member of the executive leadership team.

Risks

• Continued selling by insiders may be perceived negatively by the market, potentially impacting short-term share price volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine in the biotechnology sector and generally do not signal a change in company fundamentals or management confidence.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the pre-planned nature mitigates concerns regarding negative sentiment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Disc Medicine, IRON, Insider Trading, Form 4, Biotech, Executive Stock Sale